CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease - PubMed (original) (raw)

. 2006 Nov;129(Pt 11):3035-41.

doi: 10.1093/brain/awl269. Epub 2006 Sep 29.

Affiliations

CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease

Katharina Buerger et al. Brain. 2006 Nov.

Abstract

Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.

PubMed Disclaimer

Comment in

MeSH terms

Substances

LinkOut - more resources